[A24-36] Efgartigimod alfa (generalized myasthenia gravis) – Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2024
Project no.: A24-36
Commission: Commission awarded on 02.04.2024 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Head and nerves
Adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis for whom add-on therapy to standard therapy is an option
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-36_en